Prospective, controlled interventional study to determine the benefit of a clinical pharmacist on a German intensive care unit

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00013184

Enrollment

122

Registered

2017-12-07

Start date

2016-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

medication errors

Interventions

Group 1: Controlgroup Patients aged 18 and older, admitted on a surgical intensive care unit without any pharmaceutical care.All medical records of patients included were screened for drug related pro

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients aged 18 years and older were included in the study population if they stayed on the ICU for 24 hours or longer (work days only). If a discharged patient (that had not recieved any pharmaceutical care in the meantime) returned within 72 hours, the patient was still a part of the study population.

Exclusion criteria

Exclusion criteria: lack of documentation - if less than 24h of the stay are documented in the patients’ medical records - if more than 5% of the medical records are missing patients only admitted for monitoring palliative patients

Design outcomes

Primary

Measure	Time frame
The primary outcome is the number of medication errors detected. A medication error was defined as a deviation from the ideal medication process for the specific patient, which causes or could cause a preventable damage. DRP (drug related problem) detected by the clinical pharmacist are counted as medication errors (ME) if the chief or senior physician agrees. ME caused by nursing staff are excluded. If the same medication error occurs for several days, it counts each day.	—

Measure

Time frame

The primary outcome is the number of medication errors detected. A medication error was defined as a deviation from the ideal medication process for the specific patient, which causes or could cause a preventable damage. DRP (drug related problem) detected by the clinical pharmacist are counted as medication errors (ME) if the chief or senior physician agrees. ME caused by nursing staff are excluded. If the same medication error occurs for several days, it counts each day.

—

Secondary

Measure	Time frame
Secondary outcomes are the number of medication errors rated as potentially severe (if they could lead to organ damage, a prolongation of the length of stay, increased mortality or costs of more than 100€ per day), drug expanses ( with and without additional fees and new examination and treatment methods) (counting the storage before and after), staff salaries (documentation of the time needed by doctors and pharmacists), the number of monitored days without systemic anti-infective therapy and a fictitious length of stay. These data are colected from the patients' records. The possibility of a discharge from the ICU was assessed using the criteria "no more invasive mechanical ventilation needed and no need for neither catecholamines or alpha-2-agonists I.V. and no further reasons prohibiting a discharge. The data is collected for the time of the patients' Intensive Care Unit stay.	—

Measure

Time frame

Secondary outcomes are the number of medication errors rated as potentially severe (if they could lead to organ damage, a prolongation of the length of stay, increased mortality or costs of more than 100€ per day), drug expanses ( with and without additional fees and new examination and treatment methods) (counting the storage before and after), staff salaries (documentation of the time needed by doctors and pharmacists), the number of monitored days without systemic anti-infective therapy and a fictitious length of stay. These data are colected from the patients' records. The possibility of a discharge from the ICU was assessed using the criteria "no more invasive mechanical ventilation needed and no need for neither catecholamines or alpha-2-agonists I.V. and no further reasons prohibiting a discharge. The data is collected for the time of the patients' Intensive Care Unit stay.

—

Countries

Germany

Contacts

Public ContactDamaris Meyn

Gesundheit Nordhessen Holding AG

damaris.meyn@gnh.net056198019758

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026